TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10589001

Group type: EXPERIMENTAL
Intervention: 0.16 ppm ozone for 7.6 hours
Number of subjects: 9

Group type: COMPARATOR
Intervention: Clean air
Number of subjects: 9
Study: 8668558

Group type: EXPERIMENTAL
Intervention: Changes in mealtime context and mealtime interactions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Field experimentation in nursing
Number of subjects: 0
Study: 1836339

Group type: EXPERIMENTAL
Intervention: Centrifugal pump (CP, Biomedicus)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Roller pump (RP, Stöckert)
Number of subjects: 50
Study: 7055527

Group type: EXPERIMENTAL
Intervention: Diazepam 20 mg (male) / Diazepam 10 mg (female) via Z-track injection technique
Number of subjects: 185

Group type: COMPARATOR
Intervention: Hydroxyzine 100 mg i.m.
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Diazepam via Z-track injection technique
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Diazepam via other injection techniques (not specified)
Number of subjects: 185
Study: 30644827

Group type: EXPERIMENTAL
Intervention: Dentin bleached with 10% carbamide peroxide (CP) (at-home bleaching)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dentin bleached with 35% hydrogen peroxide (HP) (in-office bleaching)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 30
Study: 28017916

Group type: EXPERIMENTAL
Intervention: Blue light smartphone use
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional LED smartphone use
Number of subjects: 22
Study: 27206905

Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg
Number of subjects: 1053

Group type: COMPARATOR
Intervention: iDMT
Number of subjects: 1053
Study: 25153538

Group type: EXPERIMENTAL
Intervention: Alectinib (300-900 mg twice a day)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Alectinib (300-600 mg twice a day)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Alectinib (900 mg twice a day)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Alectinib (not specified dose)
Number of subjects: 47
Study: 22579443

Group type: EXPERIMENTAL
Intervention: Plastic wound retractor
Number of subjects: 250
Study: 20933178

Group type: EXPERIMENTAL
Intervention: Atomoxetine (1.2 mg/kg per day, reached at 3 weeks)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 48
Study: 17657599

Group type: EXPERIMENTAL
Intervention: Perindopril 8 mg once daily
Number of subjects: 333

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 333
Study: 15866769

Group type: EXPERIMENTAL
Intervention: Treatment for elevated blood lead concentrations (20-44 microg/dL)
Number of subjects: 0
Study: 11401051

Group type: EXPERIMENTAL
Intervention: Significant nasal symptoms (blocked nose, sneezing, nasal discharge, thick yellow nasal discharge)
Number of subjects: 8469

Group type: EXPERIMENTAL
Intervention: Nasal symptoms
Number of subjects: 8469

Group type: EXPERIMENTAL
Intervention: Nasal symptoms due to exposure to animals
Number of subjects: 8469

Group type: EXPERIMENTAL
Intervention: Nasal symptoms due to damp/cold air
Number of subjects: 8469
Study: 9728588

Group type: EXPERIMENTAL
Intervention: Gemcitabine with concurrent radiation therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cisplatin and vinblastine as induction chemotherapy
Number of subjects: 0
Study: 8067834

Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic surgery (VATS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Thoracotomy
Number of subjects: 60
Study: 3051878

Group type: EXPERIMENTAL
Intervention: N alpha-triglycyl-lysine vasopressin
Number of subjects: 71

Group type: COMPARATOR
Intervention: Lysine vasopressin
Number of subjects: 71
Study: 31390349

Group type: EXPERIMENTAL
Intervention: Brief relaxation intervention plus verbal suggestions
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Brief relaxation intervention only
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Verbal suggestions only
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 120
Study: 28874797

Group type: EXPERIMENTAL
Intervention: CT + Cet
Number of subjects: 104

Group type: COMPARATOR
Intervention: CT
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: CT + Cet + Bev
Number of subjects: 104

Group type: COMPARATOR
Intervention: CT + Bev
Number of subjects: 104
Study: 26448264

Group type: EXPERIMENTAL
Intervention: Perampanel 2, 4, 8, or 12 mg
Number of subjects: 1480

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1480

Group type: EXPERIMENTAL
Intervention: Perampanel
Number of subjects: 1480
Study: 23596815

Group type: EXPERIMENTAL
Intervention: Periplaneta americana extract plus conventional medication for sepsis
Number of subjects: 66

Group type: COMPARATOR
Intervention: Conventional treatment only
Number of subjects: 66
Study: 21312348

Group type: EXPERIMENTAL
Intervention: Multidisciplinary team care program (12 weeks, 1 day per week; individual treatments, group exercises, and group education)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Usual outpatient care
Number of subjects: 53
Study: 19416227

Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% ointment
Number of subjects: 568

Group type: COMPARATOR
Intervention: Fluticasone 0.005% ointment
Number of subjects: 568
Study: 17161948

Group type: EXPERIMENTAL
Intervention: Difficult cognitive task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Easy cognitive task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Balance tasks (easy and difficult)
Number of subjects: 0
Study: 14735556

Group type: EXPERIMENTAL
Intervention: 900 MHz cellular phone exposure (2 W)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 1800 MHz cellular phone exposure (1 W)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 32
Study: 10983642

Group type: EXPERIMENTAL
Intervention: ZDV + 3TC + indinavir (IDV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ZDV + delavirdine (DLV) + indinavir (IDV)
Number of subjects: 0
Study: 8696355

Group type: EXPERIMENTAL
Intervention: Biofeedback (BF) combined with pelvic floor muscle training (PFMT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pelvic floor muscle training (PFMT) alone
Number of subjects: 40
Study: 1553169

Group type: EXPERIMENTAL
Intervention: Interceed(TC7)
Number of subjects: 63
Study: 3892184

Group type: EXPERIMENTAL
Intervention: Quality assurance cycle intervention
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control tasks (blinded)
Number of subjects: 16
Study: 30574797

Group type: EXPERIMENTAL
Intervention: HTX-019 130 mg via 2-min injection (9 ml/min)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: HTX-019 130 mg via 30-min infusion (296 ml/h)
Number of subjects: 74

Group type: COMPARATOR
Intervention: HTX-019 130 mg via injection
Number of subjects: 74

Group type: COMPARATOR
Intervention: HTX-019 130 mg via infusion
Number of subjects: 74
Study: 28012197

Group type: EXPERIMENTAL
Intervention: Light split into 5 fractions
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Light split into 2 fractions
Number of subjects: 39

Group type: COMPARATOR
Intervention: Without light
Number of subjects: 39
Study: 27702399

Group type: EXPERIMENTAL
Intervention: Work anxiety-coping group
Number of subjects: 123

Group type: COMPARATOR
Intervention: Recreational group
Number of subjects: 123
Study: 24888810

Group type: EXPERIMENTAL
Intervention: Figitumumab (20 mg/kg) plus paclitaxel (200 mg/m(2)) and carboplatin (AUC 6 mg · min/mL)
Number of subjects: 671

Group type: COMPARATOR
Intervention: Paclitaxel and carboplatin alone
Number of subjects: 671
Study: 23082142

Group type: EXPERIMENTAL
Intervention: GnRH agonists
Number of subjects: 0

Group type: COMPARATOR
Intervention: GnRH antagonists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GnRH agonists and GnRH antagonists
Number of subjects: 0
Study: 19923505

Group type: COMPARATOR
Intervention: Morphine IV 20 microg x kg(‐1) x h(‐1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% 0.1 mL x kg(‐1) x h(‐1) via FIC catheter
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 30
Study: 17691875

Group type: EXPERIMENTAL
Intervention: Physician-delivered tailored intervention
Number of subjects: 139

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 139
Study: 14985991

Group type: EXPERIMENTAL
Intervention: Training group (n=8)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (n=8)
Number of subjects: 16
Study: 12730354

Group type: EXPERIMENTAL
Intervention: Dynorphin A1‐13 (120 microg/kg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Dynorphin A1‐13 (500 microg/kg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 10215751

Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of recombinant human growth hormone (rhGH) at a dose of 0.6 IU
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of recombinant human growth hormone (rhGH) at a dose of 1.2 IU
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of recombinant human growth hormone (rhGH) at a dose of 1.8 IU
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Intravenous injection of recombinant human growth hormone (rhGH) at a dose of 1 IU
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of recombinant human growth hormone (rhGH)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Physiological GH profile in healthy females
Number of subjects: 28
Study: 8932510

Group type: EXPERIMENTAL
Intervention: Exercise echocardiography
Number of subjects: 118
Study: 1881996

Group type: EXPERIMENTAL
Intervention: Nicotine (2 mg gum)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg capsule)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Alcohol (30 g)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (for nicotine)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (for caffeine)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (for alcohol)
Number of subjects: 10
Study: 6219455

Group type: EXPERIMENTAL
Intervention: Prednisone (oral administration)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (oral administration)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Orchiectomy without additional therapy (observation)
Number of subjects: 34
Study: 3873813

Group type: EXPERIMENTAL
Intervention: Hexabrix
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hexabrix-20
Number of subjects: 50
Study: 30201054

Group type: EXPERIMENTAL
Intervention: Financial incentive of €30 a month for 12 months for medication adherence.
Number of subjects: 133

Group type: COMPARATOR
Intervention: Care as usual (control group).
Number of subjects: 133
Study: 26612093

Group type: EXPERIMENTAL
Intervention: Cefepime (CEF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Piperacillin-tazobactam (PIP-TAZO)
Number of subjects: 40
Study: 25266289

Group type: EXPERIMENTAL
Intervention: MK-5172 (100-800 mg/day) plus pegylated interferon alfa/ribavirin (peg-IFN/RBV)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: MK-5172 100 mg arm
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: MK-5172
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: MK-5172 200 mg group
Number of subjects: 266
Study: 24231014

Group type: EXPERIMENTAL
Intervention: Very early enteral nutrition (nasojejunal feeding starting within four hours after admission)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard diet (three standard hospital meals per os after the first wound dressing)
Number of subjects: 101
Study: 20473064

Group type: EXPERIMENTAL
Intervention: Low-dose olanzapine (1 mg/d)
Number of subjects: 422

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Active drug (haloperidol 10-20 mg/d or medium-high dose olanzapine 7.5-17.5 mg/d)
Number of subjects: 422
Study: 19267094

Group type: EXPERIMENTAL
Intervention: Current smoking prevalence among individuals aged 15-24 years
Number of subjects: 3057

Group type: EXPERIMENTAL
Intervention: Overall smoking prevalence
Number of subjects: 3057

Group type: EXPERIMENTAL
Intervention: Intention to quit smoking
Number of subjects: 3057

Group type: EXPERIMENTAL
Intervention: Trends in smoking prevalence
Number of subjects: 3057
Study: 15667369

Group type: EXPERIMENTAL
Intervention: Functional-task exercise program (function group, n=33)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Resistance exercise program (resistance group, n=34)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (n=31)
Number of subjects: 98
Study: 12743537

Group type: EXPERIMENTAL
Intervention: Diabetic patients (n=51)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (n=28)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Diabetic patients with peripheral neuropathy (group B, n=13)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Diabetic patients with autonomic neuropathy (group C, n=13)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Diabetic patients without neuropathy (group A, n=18)
Number of subjects: 51
Study: 10725526

Group type: EXPERIMENTAL
Intervention: Low HDL cholesterol levels in patients with a history of aggression
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Low HDL cholesterol levels
Number of subjects: 38
Study: 8863773

Group type: EXPERIMENTAL
Intervention: AS-1 RBCs stored for ≤ 42 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: CPDA-1 RBCs stored for ≤ 7 days
Number of subjects: 0
Study: 1736342

Group type: EXPERIMENTAL
Intervention: Screening group (Hemoccult‐II performed at least once)
Number of subjects: 61938

Group type: COMPARATOR
Intervention: Non-responders to screening
Number of subjects: 61938

Group type: EXPERIMENTAL
Intervention: Negative Hemoccult‐II
Number of subjects: 61938

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61938
Study: 6476835

Group type: EXPERIMENTAL
Intervention: Etoposide (NK 171) intravenously at a dose of 100‐130 mg/m2/day for five days
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Etoposide (NK 171) orally at a dose of 130‐170 mg/m2/day for five days
Number of subjects: 17
Study: 30730931

Group type: EXPERIMENTAL
Intervention: Self-care recommendations adherence
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Being male
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Good level of heart failure knowledge
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Free from chronic comorbid diseases
Number of subjects: 310
Study: 30256551

Group type: EXPERIMENTAL
Intervention: Customized adherence enhancement (CAE)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Bipolar-specific educational program (EDU)
Number of subjects: 184
Study: 25772003

Group type: EXPERIMENTAL
Intervention: Video feedback intervention
Number of subjects: 10
Study: 25293882

Group type: EXPERIMENTAL
Intervention: Niaspan FCT™ (extended-release niacin)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Antiretroviral therapy alone
Number of subjects: 20
Study: 22887972

Group type: EXPERIMENTAL
Intervention: Prediction rule developed from the derivation set
Number of subjects: 3459
Study: 19933747

Group type: EXPERIMENTAL
Intervention: 700/400 kappa, rate responsive pacemaker
Number of subjects: 141

Group type: COMPARATOR
Intervention: Implantable loop recorder (Medtronic Reveal thera RDR)
Number of subjects: 141
Study: 17388753

Group type: EXPERIMENTAL
Intervention: Novolizer (PIF‐N)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Turbuhaler (PIF‐T)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Comparison of Novolizer and Turbuhaler
Number of subjects: 46

Group type: COMPARATOR
Intervention: Novolizer (PIF‐N) vs Turbuhaler (PIF‐T)
Number of subjects: 46
Study: 16142294

Group type: EXPERIMENTAL
Intervention: Cell therapy (cell suspension from immature nervous and hemopoietic tissues)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (clinically comparable)
Number of subjects: 10
Study: 11865831

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PXF) 1600 mg daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 9797089

Group type: EXPERIMENTAL
Intervention: Abstained from alcohol and consumed less than one cup of coffee or its equivalent per day
Number of subjects: 124

Group type: COMPARATOR
Intervention: Consumed any alcohol and more than one cup of coffee per day
Number of subjects: 124
Study: 7650184

Group type: EXPERIMENTAL
Intervention: BioStar Strep A OIA optical immune assay
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Abbott TestPack Plus Strep A
Number of subjects: 500

Group type: COMPARATOR
Intervention: Culture with selective media
Number of subjects: 500
Study: 2814944

Group type: EXPERIMENTAL
Intervention: Co‐dergocrine mesylate (Hydergine)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 857691

Group type: EXPERIMENTAL
Intervention: 0.6 vol.% enflurane (group I)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 0.6 and 0.8 vol.% enflurane (group II)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 22
Study: 30414855

Group type: EXPERIMENTAL
Intervention: ZPL-3893787 (30 mg once-daily oral therapy)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 29284500

Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: CFS patients
Number of subjects: 50
Study: 27176144

Group type: EXPERIMENTAL
Intervention: High sodium diet (167 mmol/day) for 3 weeks
Number of subjects: 35

Group type: COMPARATOR
Intervention: Low sodium diet (57 mmol/day) for 3 weeks
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: High sodium diet (167 mmol/day)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Low sodium diet (57 mmol/day)
Number of subjects: 35
Study: 24331269

Group type: EXPERIMENTAL
Intervention: Sublingual hyoscyamine sulfate
Number of subjects: 92
Study: 21815451

Group type: EXPERIMENTAL
Intervention: Modified mono‐pigtail stent (Group 1, n=65)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard double‐pigtail stent (Group 2, n=65)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Comparison of stent‐related symptoms
Number of subjects: 130
Study: 19216779

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 17974032

Group type: COMPARATOR
Intervention: Glucosamine sulfate (1500 mg/day)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Reparagen (1800 mg/day)
Number of subjects: 95
Study: 15162947

Group type: EXPERIMENTAL
Intervention: High-dose phenobarbital therapy (40 mg/kg during the first 60 min after birth)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Conventional doses of phenobarbital (only if clinical evidence of seizures)
Number of subjects: 73
Study: 11220254

Group type: EXPERIMENTAL
Intervention: Clonidine (3 microg/kg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Esmolol (2 mg/kg)
Number of subjects: 44
Study: 9389827

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (81 mg/d)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard hormone replacement without aspirin (Control)
Number of subjects: 28
Study: 7894214

Group type: EXPERIMENTAL
Intervention: Human leukocyte alpha-interferon cream (2 x 10(6) IU/g) applied thrice a day for 3 consecutive days (group A) or 4 consecutive days (group B) per week, for a maximum of 4 weeks.
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo cream applied in the same manner as the active treatment.
Number of subjects: 150
Study: 3120436

Group type: EXPERIMENTAL
Intervention: 0.025 mg nitroglycerin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 28957728

Group type: EXPERIMENTAL
Intervention: Nicotine (4 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotine (4 mg) in participants with greater nicotine dependence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotine on Day 1 or Placebo on Day 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotine on Day 2
Number of subjects: 0
Study: 27587328

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 19114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19114
Study: 24042066

Group type: EXPERIMENTAL
Intervention: Lysine clonixinate plus tramadol (LC 125 mg + T 25 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Tramadol (T) alone (50 mg)
Number of subjects: 40
Study: 22738270

Group type: EXPERIMENTAL
Intervention: Needling at TE5
Number of subjects: 43

Group type: COMPARATOR
Intervention: Sham needling at TE5
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Needling/sham needling at TE5
Number of subjects: 43

Group type: COMPARATOR
Intervention: Sham needling at the sham point
Number of subjects: 43

Group type: COMPARATOR
Intervention: Needling at the sham point
Number of subjects: 43
Study: 21034646

Group type: EXPERIMENTAL
Intervention: Pulmonary artery perfusion with hypothermic HTK solution
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no pulmonary artery perfusion)
Number of subjects: 24
Study: 17482611

Group type: EXPERIMENTAL
Intervention: Intrauterine insemination for 6 months
Number of subjects: 51

Group type: COMPARATOR
Intervention: Expectant management for 6 months
Number of subjects: 51
Study: 15755850

Group type: EXPERIMENTAL
Intervention: Metformin (425 mg/d) for 6 months in SGA-PP girls
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH, 60 mug/kg/d) in SGA-SS children
Number of subjects: 62

Group type: COMPARATOR
Intervention: Untreated SGA-PP girls
Number of subjects: 62

Group type: COMPARATOR
Intervention: Untreated SGA-SS children
Number of subjects: 62
Study: 11916785

Group type: EXPERIMENTAL
Intervention: GAN block with 2 mL of 0.25% bupivacaine with epinephrine (1:200,000) and a sham IV injection of 2 mL of saline solution
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: GAN block with 2 mL of 0.25% bupivacaine with epinephrine (1:200,000)
Number of subjects: 40

Group type: COMPARATOR
Intervention: IV morphine sulfate (0.1 mg/kg diluted to 2 mL)
Number of subjects: 40
Study: 8682014

Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg daily for 2 weeks, then 200 mg daily for 2 years
Number of subjects: 967

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 967

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 967
Study: 2676908

Group type: EXPERIMENTAL
Intervention: Ibuprofen (initial dose 800 mg, additional 400 mg as needed)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40